Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520065 | 0.91 | NPC1 (0.59) | NPC1RAB9AL3MBTL1KMT2AMEN1 | |
| SCHEMBL520364 | 0.89 | NPC1 (0.58) | NPC1RAB9AL3MBTL1KMT2AMEN1 | |
| SCHEMBL31350203 | 0.88 | NPC1 (0.57) | NPC1RAB9AL3MBTL1KMT2AMEN1 | |
| SCHEMBL19491933 | 0.86 | MEN1 (0.64) | NPC1RAB9AL3MBTL1KMT2AMEN1 | |
| SCHEMBL29235094 | 0.85 | NPC1 (0.61) | NPC1RAB9AL3MBTL1KMT2AMEN1 | |
| SCHEMBL22638725 | 0.84 | NPC1 (0.63) | NPC1RAB9AL3MBTL1KMT2AMEN1 | |
| SCHEMBL20122609 | 0.82 | NPC1 (0.53) | NPC1RAB9AL3MBTL1KMT2AMEN1 | |
| SCHEMBL7326923 | 0.81 | NPC1 (0.50) | NPC1RAB9AL3MBTL1KMT2AMEN1 | |
| SCHEMBL3767544 | 0.81 | NPC1 (0.52) | NPC1RAB9AL3MBTL1KMT2AMEN1 | |
| SCHEMBL31552050 | 0.80 | NPC1 (0.49) | NPC1RAB9AL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104892582-B | Azetidine as the mek inhibitor for treating proliferative disease | 埃克塞利希斯股份有限公司 | 2019-09-27 | — | — | CN | disclosed |
| US-8044103-B2 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | GEORGETOWN UNIVERSITY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | KOZIKOWSKI ALAN P | 2007-07-12 | — | — | US | disclosed |
| US-7202279-B1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | GEORGETOWN UNIVERSITY (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1061936-A4 | CYCLIC DIPEPTIDES AND AZETIDINONE COMPOUNDS AND THEIR USE IN TREATING CNS INJURY AND NEURODEGENERATIVE DISORDERS | UNIV GEORGETOWN (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1061936-A1 | CYCLIC DIPEPTIDES AND AZETIDINONE COMPOUNDS AND THEIR USE IN TREATING CNS INJURY AND NEURODEGENERATIVE DISORDERS | GEORGETOWN UNIVERSITY (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999040931-A1 | CYCLIC DIPEPTIDES AND AZETIDINONE COMPOUNDS AND THEIR USE IN TREATING CNS INJURY AND NEURODEGENERATIVE DISORDERS | GEORGETOWN UNIVERSITY (US) | 1999-08-19 | — | — | WO | disclosed |
| US-5068331-A | Certain (2-carboxy or 2-propenoic or 2-carbonyl)-3-halo-4,5-dioxy pyridine intermediates and the corresponding 1,4-dihydro-4-pyridones) | E. R. SQUIBB & SONS, INC. (US) | 1991-11-26 | — | — | US | disclosed |
| US-4959470-A | 2-oxo-[[(substituted sulfonyl)-amino]carbonyl]-azetidines | E. R. SQUIBB & SONS, INC. (US) | 1990-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | BDNF, PMP22, ADAM17 | NPC1 1247/4885RAB9A 2790/4885L3MBTL1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.